

Ulcerative Colitis

**A study in the use of etrolizumab in patients with ulcerative colitis  
(Eucalyptus)**

Evaluate the Efficacy and Safety of rhuMAb Beta7 in Patients With Moderate to Severe Ulcerative Colitis

**Trial Status**  
Completed

**Trial Runs In**  
11 Countries

**Trial Identifier**  
NCT01336465 GP27778  
ABS4986g

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

***Trial Summary:***

This Phase II study is a randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of rhuMAb Beta7 in patients with moderate to severe ulcerative colitis.

**Genentech, Inc.**  
Sponsor

**Phase 2**  
Phase

---

**NCT01336465 GP27778 ABS4986g**  
Trial Identifiers

---

***Eligibility Criteria:***

**Gender**  
All

**Age**  
>=18 Years & <= 75 Years

**Healthy Volunteers**  
No

---